Superworth

Maze Therapeutics price to book ratio MAZE

Market value divided by the book value of the company's net assets, since 2025.

Today, Nov 2, 2026
3.7×
Peer median
5.4×

Maze Therapeutics' price to book ratio is 3.7× as of Nov 2, 2026.

The median for 9 biotech stocks of a similar size is 5.4×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.7×2.8×6.4×
20255.3×1.4×5.5×

Against its peers

Companies in Biotechnology nearest Maze Therapeutics' size, closest first, today.

CompanyPrice to book ratio
MAZEMaze Therapeutics3.7×
VCELVericel5.6×
ADMAAdma Biologics6.1×
MGTXMeiraGTx4.2×
KRYSKrystal Biotech6.4×
RGENRepligen4.6×
TECHBIO-TECHNE5.4×
PLXProtalix BioTherapeutics2.9×
HALOHalozyme Therapeutics102×
NBIXNeurocrine Biosciences4.0×
Peer median5.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Maze Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.